A Phase I Study to Investigate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of BR111 for Injection in Patients With Advanced Malignancies
Latest Information Update: 10 May 2025
At a glance
- Drugs BR 111 (Primary)
- Indications B-cell lymphoma; Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors BioRay Pharmaceutical
Most Recent Events
- 25 Apr 2025 Status changed from planning to not yet recruiting.
- 20 Feb 2025 New trial record
- 10 Feb 2025 According to a BioRay Pharmaceutical media release, the National Medical Products Administration (NMPA) has accepted the clinical trial application for BR111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.